Tower Research Capital LLC (Trc) Annovis Bio, Inc. Call Options Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANVS
# of Institutions
50Shares Held
1.99MCall Options Held
348KPut Options Held
535K-
Vanguard Group Inc Valley Forge, PA648KShares$958,9210.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il215KShares$318,5060.0% of portfolio
-
Ubs Group Ag161KShares$238,0960.0% of portfolio
-
Geode Capital Management, LLC Boston, MA153KShares$225,8670.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$149,0490.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $12.1M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...